Antidepresanların Yan Etkileri
Özet
Antidepresanlar, dünya çapında işlev kaybının önde gelen nedenlerinden biri olan depresyonun yanı sıra anksiyete, panik atak ve obsesif kompulsif bozukluk gibi rahatsızlıkların tedavisinde ilk basamak seçenekleridir. Bu ilaçlar serotonin, noradrenalin ve dopamin gibi monoaminlerin iletimini artırarak etki gösterirler. En yaygın kullanılanlar seçici serotonin geri alım inhibitörleri (SSRI) ve serotonin-noradrenalin geri alım inhibitörleridir (SNRI). Hastaların yaklaşık %60'ı hafif ila şiddetli yan etkiler yaşamakta ve bu durum tedaviyi bırakma konusunda önemli bir bariyer oluşturmaktadır. Yaygın fiziksel ve gastrointestinal yan etkiler arasında baş ağrısı, mide bulantısı, kusma, uyku bozuklukları, terleme, kilo alımı ve cinsel işlev bozuklukları yer alır. Ayrıca, bazı hastalarda kardiyovasküler etkiler (QT aralığı uzaması, kan basıncı artışı), ilaca bağlı karaciğer toksisitesi, kemik mineral yoğunluğunda azalma ve artmış kanama riski gibi daha ciddi komplikasyonlar gözlenebilir. Genç yaş gruplarında intihar eğiliminin izlenmesi gerekirken, ilaçların aniden veya kademeli olarak bırakılması durumunda grip benzeri semptomlar, titreme ve anksiyete içeren geri çekilme sendromu ortaya çıkabilmektedir. Özetle, yeni nesil antidepresanlar eski tiplere göre daha güvenli olsalar da geniş bir yan etki profiline sahiptirler ve idame tedavisinde nüks riskini azalttıkları için hastaların olası etkiler hakkında eğitilmeleri tedavi uyumu açısından kritik öneme sahiptir.
Antidepressants are first-line treatment options for depression, which is a leading cause of disability worldwide, as well as for anxiety, panic attacks, and obsessive-compulsive disorder. These medications exert their effects by increasing the transmission of monoamines such as serotonin, noradrenaline, and dopamine. The most commonly used types are selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs). Approximately 60% of patients experience mild to severe side effects, which creates a significant barrier to discontinuing treatment. Common physical and gastrointestinal side effects include headache, nausea, vomiting, sleep disturbances, sweating, weight gain, and sexual dysfunction. Furthermore, more serious complications such as cardiovascular effects (QT interval prolongation, increased blood pressure), drug-induced liver toxicity, decreased bone mineral density, and increased risk of bleeding can be observed in some patients. While suicidal tendencies must be monitored in younger populations, discontinuation syndrome, which includes flu-like symptoms, tremors, and anxiety, may occur upon abrupt or gradual cessation of the medication. In conclusion, although next-generation antidepressants possess a better safety profile than older types, they have a wide range of side effects; since they reduce the risk of relapse during maintenance treatment, educating patients about potential effects is of critical importance for treatment adherence.
Referanslar
Seppala LJ, Wermelink AMAT, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG et al., Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc (2018); 19(4)
Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 2018; 2;343:d4551.
Kok RM, Reynolds CF, Management of depression in older adults: a review. JAMA; 2017, 317(20):2114–2122
Kirsch I, Deacon B, Huedo-Medina T, et al. Initial Severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. PLOS Med 2008;5(2):e45. www.plosmedicine.org
Papakostas G, Perlis R, Scalia M, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharm 2006;26:56-60.
Geddes J, Carner S, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-61.
Cipriani A, Furukawra T, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
Stahl S. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition plus melatonergic agonism. Int J Neuropsychopharm 2007;10:575-8.
Diler RS, Avci A. Selective serotonin reuptake inhibitor discontinuation syndrome in children: six case reports. Curr Ther Res 2002;63:188–97.
van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005;61:303–07.
E mslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): Safety Results. J Am Acad Child Adolesc Psychiatry 2006;45:1440–55.
E mslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): Safety Results. J Am Acad Child Adolesc Psychiatry 2006;45:1440–55.
Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008;359:2753–66.
Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006;45:1151–61.
Gordon M., Melvin G., Selective serotonin re-uptake inhibitors A review of the side effects in adolescents, Australian Family Physician Vol. 42, No. 9, september 2013
Voican CS, Corruble E, Naveau S, Perlemuter G: Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404–415.
Chen M, Borlak J, Tong W: High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388–396
Fava M: Weight gain and antidepressants. J Clin Psychiatry 2000; 61(suppl 1):37–41.
Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259–1272.
Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T: Epidemiology, implications and mechanisms underlying druginduced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193–220.
Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong ML: Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry 2016; 6:e759.
Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R, Pereira AC, Ribeiro ALP, Mill JG, Andreão RV, Thayer JF, Benseñor IM, Lotufo PA: Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am J Psychiatry 2014; 171: 1328–1334.
Goldstein DJ: Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007; 3: 193–209.
O’Regan C, Kenny RA, Cronin H, Finucane C, Kearney PM: Antidepressants strongly influence the relationship between depression and heart rate variability: findings from the Irish longitudinal study on ageing (TILDA). Psychol Med 2015; 45: 623–636.
Taylor CB: Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol 2010; 78: 80–88. 77
Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME: An overview of vortioxetine. J Clin Psychiatry 2014; 75: 1411– 1418.
Funk KA, Bostwick JR: A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013; 47: 1330–1341.
Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC: QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54: 1–13.
Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ: Cardiovascular profile of duloxetine, a dual reuptake inhibitör of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25: 132–140.
Darowski A, Chambers SA, Chambers DJ: Antidepressants and falls in the elderly. Drugs Aging 2009; 26: 381–394.
Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC: Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75:e441–e449.
Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H: Patients’ attitudes toward side effects of antidepressants: an internet survey. Eur Arch Psychiatry Clin Neurosci 2011; 261: 103–109.
Balon R, Segraves RT: Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther 2008; 34: 353–365.
Bella AJ, Shamloul R: Psychotropics and sexual dysfunction. Cent Eur J Urol 2013; 66: 466–471.
Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, van Noord M, Lux L, Gaynes BN: Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014; 37: 19–31.
Gartlehner GH, Hansen RA, Reichenpfader UK, Kaminski A, Kien C, Strobelberger MN, van Noord M, Thieda P, Thaler K, Gaynes B: Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report. Drug Class Reviews. Portland, Oregon Health and Science University, 2011.
Montejo AL, Montejo L, Navarro-Cremades F: Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015; 28: 418–423.
Rosenblat JD, Gregory JM, Carvalho AF, McIntyre RS: Depression and disturbed bone metabolism: a narrative review of the epidemiological findings and postulated mechanisms. Curr Mol Med 2016; 16: 165–178.
Cizza G, Primma S, Csako G: Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 2009; 20: 367–373.
Wu Q, Bencaz AF, Hentz JG, Crowell MD: Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23: 365–375.
Vestergaard P, Rejnmark L, Mosekilde L: Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008; 82: 92–101.
Andrade C, Sandarsh S, Chethan KB, Nagesh KS: Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565–1575.
de Abajo FJ: Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28: 345–367.
Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23(suppl 1):15–26.
Hawthorne JM, Caley CF: Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 2015; 49: 1136–1152.
Schillevoort I, van Puijenbroek EP, de Boer A, Roos RAC, Jansen PAF, Leufkens HGM: Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17: 75–79.
Madhusoodanan S, Alexeenko L, Sanders R, Brenner R: Extrapyramidal symptoms associated with antidepressants – a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148–156.
Hedenmalm K, Güzey C, Dahl M-L, Yue Q-Y, Spigset O: Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192–197.
Konstantakopoulos G, Kouzoupis AV, Papageorgiou SG, Oulis P: Putative neuroleptic malignant syndrome associated with sertraline withdrawal. J Clin Psychopharmacol 2009; 29: 300–301.
Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352: 1112–1120. 144 Iqbal MM, Basil MJ, Kaplan J, Iqbal MT: Overview of serotonin syndrome. Ann Clin Psychiatry 2012; 24: 310–318.
Isbister GK, Bowe SJ, Dawson A, Whyte IM: Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42: 277–285.
Ashton AK, Weinstein WL: Cyproheptadine for drug-induced sweating. Am J Psychiatry 2002; 159: 874–875.
Marcy TR, Britton ML: Antidepressant-induced sweating. Ann Pharmacother 2005; 39: 748–752.
Arfken CL, Joseph A, Sandhu GR, Roehrs T, Douglass AB, Boutros NN: The status of sleep abnormalities as a diagnostic test for major depressive disorder. J Affect Disord 2014; 156: 36–45.
Wilson S, Argyropoulos S: Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927–947.
Tribl GG, Wetter TC, Schredl M: Dreaming under antidepressants: a systematic review on evidence in depressive patients and healthy volunteers. Sleep Med Rev 2013; 17: 133–142.
Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335:142.
Pozzi M, Radice S, Clementi E, Molteni M, Nobile M: Antidepressants and, suicide and self-injury: causal or casual association? Int J Psychiatry Clin Pract 2016; 20: 47–51.
Leon AC, Fiedorowicz JG, Solomon DA, Li C, Coryell WH, Endicott J, Fawcett J, Keller MB: Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. J Clin Psychiatry 2014; 75: 720–727.
Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M: Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007; 15: 133–145.
Stone MB: The FDA warning on antidepressants and suicidality – why the controversy? N Engl J Med 2014; 371: 1668–1671.
Wilson E, Lader M: A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357–368.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72–81.
Starcevic V, Brakoulias V, Viswasam K, Berle D: Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom 2015; 84: 379–380.
Preskorn SH: Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56(suppl 6):12–21.
Trindade E, Menon D, Topfer LA, Coloma C: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245–1252.
Costagliola C, Parmeggiani F, Sebastiani A: SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 2004; 18: 475–484.
Trenque T, Herlem E, Auriche P, Drame M: Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database. Drug Saf 2011; 34: 1161–1166.
Ajmal A, Joffe H, Nachtigall LB: Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 2014; 55: 29–36.
Mondal S, Saha I, Das S, Ganguly A, Das D, Tripathi SK: A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series. Ther Adv Psychopharmacol 2013; 3: 322–334.
Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR: Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698–709.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis C-L, Koren G, Steiner M, Mousmanis P, Cheung A, Radford K, Martinovic J, Ross LE: The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74:e321–e341.
Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HED, Skaarup L, Videbech P: Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand 2015; 132: 1–28.
Reis M, Källén B: Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relativelysevere congenital malformations or cardiac defects: a register study. BMJ Open 2013; 3:e002166.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013; 74:e293–e308.
Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, Mogun H, Setoguchi S: Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013; 347:f4877.
Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; Study NBDP: Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 2015; 351:h3190.
Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and metaanalysis. BMJ 2014; 348:f6932.
Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306–311.
Fava G, Cosci F, Tomba E: Iatrogenic comorbidity in mental health. Psychother Psychosom 2015; 84(suppl 1):22.
Kaymaz N, van Os J, Loonen AJ, Nolen WA: Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69: 1423–1436.
